Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.16%
#3 Velvet Velvet +44.46%
#4 Akedo Akedo +40.57%
#5 Black Phoenix Black Phoenix +33.98%
#6 Cross Cross +24.15%
#7 Cap Cap +20.35%
#8 DoubleZero DoubleZero +14.60%
#9 Tutorial Tutorial +11.59%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.77%
Coin of the day
Islamic Coin Islamic Coin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rang in aandelen #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aandeelprijs
$0.11725176
Laatst gesynchroniseerd: 2025-07-14
Marktkapitalisatie
$481.50K
Verandering (1 dag)
-0.20%
Verandering (1 jaar)
0.00%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Categorie

Healthcare
P/S-ratio voor PHAXIAM Therapeutics S.A. (PHXM)
P/S-ratio op August 2026 TTM: 0.76
Volgens de meest recente financiële rapporten en aandelenkoers van PHAXIAM Therapeutics S.A. is de huidige P/S-ratio (TTM) 0.76. Eind 2022 had het bedrijf een P/S-ratio van 1.71.
P/S-ratiohistoriek voor PHAXIAM Therapeutics S.A. van 2016 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 0.76 -94.94%
2023 15.05 779.26%
2022 1.71 -85.75%
2021 12.01 -65.83%
2020 35.16 54.56%
2019 22.75 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 1,197.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 1,252.63%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 553.71%
BE